| Year |
Citation |
Score |
| 2011 |
Cannon JL, Mody PD, Blaine KM, Chen EJ, Nelson AD, Sayles LJ, Moore TV, Clay BS, Dulin NO, Shilling RA, Burkhardt JK, Sperling AI. CD43 interaction with ezrin-radixin-moesin (ERM) proteins regulates T-cell trafficking and CD43 phosphorylation. Molecular Biology of the Cell. 22: 954-63. PMID 21289089 DOI: 10.1091/Mbc.E10-07-0586 |
0.656 |
|
| 2010 |
DiPersio J, Nademanee A, Stiff P, Stadtmauer E, Mody P, Marulkar S, Micallef I. Defining The Optimal Threshold Of Peripheral Blood (PB) CD34+Cells To Initiate Apheresis In Patients With NHL Undergoing Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) After G-CSF Mobilization Biology of Blood and Marrow Transplantation. 16: S200. DOI: 10.1016/j.bbmt.2009.12.146 |
0.315 |
|
| 2008 |
Cannon JL, Collins A, Mody PD, Balachandran D, Henriksen KJ, Smith CE, Tong J, Clay BS, Miller SD, Sperling AI. CD43 regulates Th2 differentiation and inflammation. Journal of Immunology (Baltimore, Md. : 1950). 180: 7385-93. PMID 18490738 DOI: 10.4049/Jimmunol.180.11.7385 |
0.756 |
|
| 2007 |
Bandukwala HS, Clay BS, Tong J, Mody PD, Cannon JL, Shilling RA, Verbeek JS, Weinstock JV, Solway J, Sperling AI. Signaling through Fc gamma RIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation. The Journal of Experimental Medicine. 204: 1875-89. PMID 17664287 DOI: 10.1084/Jem.20061134 |
0.58 |
|
| 2007 |
Mody PD, Cannon JL, Bandukwala HS, Blaine KM, Schilling AB, Swier K, Sperling AI. Signaling through CD43 regulates CD4 T-cell trafficking. Blood. 110: 2974-82. PMID 17638845 DOI: 10.1182/Blood-2007-01-065276 |
0.764 |
|
| 2006 |
Cannon J, Mody P, Sperling A. Su.110. Pka and Pkd Phosphorylation of Cd43 in T-Cells Clinical Immunology. 119: S197. DOI: 10.1016/J.Clim.2006.04.537 |
0.778 |
|
| 2004 |
Tong J, Allenspach EJ, Takahashi SM, Mody PD, Park C, Burkhardt JK, Sperling AI. CD43 regulation of T cell activation is not through steric inhibition of T cell-APC interactions but through an intracellular mechanism. The Journal of Experimental Medicine. 199: 1277-83. PMID 15117976 DOI: 10.1084/Jem.20021602 |
0.787 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2010 |
Horwitz ME, Gorak E, Holman P, Libby E, Huebner D, Mody PD, Schriber JR. Efficacy and Safety of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil®) + G-CSF In Adult Patients with Non-Hematologic Malignancies Blood. 116: 2249-2249. DOI: 10.1182/blood.V116.21.2249.2249 |
0.299 |
|
| 2009 |
Micallef IN, Jacobsen E, Shaughnessy P, Marulkar S, Mody P, Rhee Fv. Plerixafor (Mozobil ®)Plus G-CSF Is Effective in Mobilizing Hematopoietic Stem Cells in Patients with Concurrent Thrombocytopenia Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood. 114: 3229-3229. DOI: 10.1182/Blood.V114.22.3229.3229 |
0.26 |
|
| 2011 |
Schriber J, Horwitz M, Libby E, Huebner D, Mody P, Holman P. Efficacy and Safety of Hematopoietic Stem Cell Remobilization With Plerixafor (Mozobil®) + G-CSF in Patients With Germ Cell Tumor Biology of Blood and Marrow Transplantation. 17: S205-S206. DOI: 10.1016/j.bbmt.2010.12.163 |
0.112 |
|
| 2010 |
Micallef I, Maziarz R, van Rhee F, Horwitz M, Hill J, Stewart K, Mody P, Huebner D, Shaughnessy P. Efficacy Of Plerixafor Plus G-CSF In Hematopoietic Stem Cell (HSC) Remobilization In Patients With Amyloidosis Biology of Blood and Marrow Transplantation. 16: S203-S204. DOI: 10.1016/j.bbmt.2009.12.154 |
0.092 |
|
| 2010 |
Horwitz M, Schriber J, Libby EN, Gorak EJ, Mody P, Marulkar S, Holman PR. Efficacy and safety of hematopoietic stem cell (HSC) remobilization with plerixafor plus G-CSF in patients with non-hematologic malignancies. Journal of Clinical Oncology. 28: e15072-e15072. DOI: 10.1200/JCO.2010.28.15_SUPPL.E15072 |
0.077 |
|
| 2017 |
Hubner R, Chen L, Li C, Bodoky G, Dean A, Lee K, Cunningham D, Siveke J, Braiteh F, de Jong F, Belanger B, Walls R, Mody P, von Hoff D, Wang-Gillam A. Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone Annals of Oncology. 28: v253. DOI: 10.1093/Annonc/Mdx369.124 |
0.027 |
|
| 2017 |
Wang-Gillam A, Chen L, Li C, Bodoky G, Dean A, Lee K, Cunningham D, Hubner R, Braiteh FS, Pipas JM, Belanger B, de Jong FA, Mody PD, Von Hoff DD, Siveke JT. The prognostic value of baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV. Journal of Clinical Oncology. 35: e15795-e15795. DOI: 10.1200/Jco.2017.35.15_Suppl.E15795 |
0.019 |
|
| 2017 |
Wang-Gillam A, Li C, Bodoky G, Dean A, Lee K, Cunningham D, Hubner R, Siveke JT, Braiteh FS, Pipas JM, Belanger B, de Jong F, Mody PD, Chen L, Von Hoff DD. Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-FU/LV. Journal of Clinical Oncology. 35: 293-293. DOI: 10.1200/Jco.2017.35.4_Suppl.293 |
0.01 |
|
| Hide low-probability matches. |